About Us - Neocytogen - 瑞元康晟生物医药有限公司

About Neocytogen

Founded in 2024, Neocytogen Therapeutics is a biotechnology company focusing on universal cell and gene therapy, committed to developing innovative therapies for malignant tumors and chronic diseases. The company's core technologies include universal CAR-X platform, iPSC platform, next generation oncolytic virus platform, and exosome technology platform. The founding team of Neocytogen is composed of senior scientists from the National University of Singapore and Nanyang Technological University. The company is headquartered in Singapore, with R&D centers in Singapore and Shanghai, China. We are also building an integrated center of R&D and production in Singapore to support future technology translation and clinical applications, enabling us to become a global leader in universal cell therapy.

Our Advantages

Focus on universal product development

Specializing in universal cell and gene therapy, it has four core technology platforms covering different disease areas. The synergy between platforms is expected to foster new treatment methods.

Deep technical accumulation

The scientific team has more than a decade of technical experience in the field of cell and gene therapy, providing a solid foundation for the development and sustainable advancement of innovative products.

Full-chain technology layout

The core technology team covers the entire process from upstream design innovation to downstream large-scale production, bringing together many high-end talents and creating a complete chain from basic research to industrialization.

Global strategic layout

The headquarters is located in Singapore, as the core hub for strategic decision-making and global operations. The Shanghai R&D Center focuses on cutting-edge biotechnology development. The Beijing Clinical Trial Base accelerates the clinical research and translation of new drugs to ensure the rapid implementation of research results.